Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06945484 · ClinicalTrials.gov registry record · NA
PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study
A NA study of NSCLC, Stage III and NSCLC Stage II, sponsored by University of Utah.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT06945484 is a NA study of NSCLC, Stage III and NSCLC Stage II that is actively recruiting participants, run by University of Utah. The registered enrollment target is 20 participants, below the 51-participant average among 3 other NSCLC, Stage III trials with a reported enrollment target (61% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06945484, a NA study of NSCLC, Stage III and NSCLC Stage II, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is designed to evaluate whether a precision exercise regimen is feasible to implement within cancer populations, specifically stage II-III primary lung cancer patients receiving multimodal therapy, and delivered through telehealth.
Conditions Studied
Interventions
- OTHER Precision Exercise Regimen for Cancer Care (PERCC)
Study Locations (2)
Texas
- University of Texas Medical Branch at Galveston - Galveston
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-11-21 |
| Est. Completion | 2030-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06945484
The ClinicalTrials.gov registry entry for NCT06945484 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 51-participant average among 3 other NSCLC, Stage III trials with a reported enrollment target (61% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with NSCLC, Stage III appearing as the primary indexed condition, and to 1 intervention - of which Precision Exercise Regimen for Cancer Care (PERCC) is the first listed.
NCT06945484 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT06945484 about?
NCT06945484 is a clinical study titled "PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study". This study is designed to evaluate whether a precision exercise regimen is feasible to implement within cancer populations, specifically stage II-III primary lung cancer patients receiving multimodal therapy, and delivered through telehealth.
What is the current status of trial NCT06945484?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-11-21. Estimated completion is 2030-12.
What conditions does trial NCT06945484 study?
This clinical trial studies the following conditions: NSCLC, Stage III, NSCLC Stage II.
What interventions are being tested in trial NCT06945484?
The interventions under investigation include: Precision Exercise Regimen for Cancer Care (PERCC) (OTHER).
Who is sponsoring clinical trial NCT06945484?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06945484 being conducted?
This trial has 2 study locations across Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC, Stage III
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
RECRUITING · Phase 3
-
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
RECRUITING
-
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.